{"url_path":"/sec/spro/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-221591-index.html","accession_number":"0001193125-26-221591","cik":"0001701108","ticker":"SPRO","issuer_name":"Spero Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1701108/0001193125-26-221591-index.html","primary_entity_key":"0001701108","primary_entity_name":"Spero Therapeutics, Inc."},"word_count":353,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n \n\nExhibit\n\nNumber\n\nExhibit Description\n\nFiled with\n\nthis Report\n\nIncorporated by\n\nReference herein from\n\nForm or Schedule\n\nFiling Date\n\nSEC File /\n\nRegistration\n\nNumber\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1701108/000119312517334318/d490191dex31.htm)\n\n \n\n \n\nForm 8-K\n\n(Exhibit 3.1)\n\n11/6/2017\n\n001-38266\n\n3.2\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1701108/000119312521250505/d198322dex31.htm)\n\n \n\n \n\nForm 8-K\n\n(Exhibit 3.1)\n\n8/18/2021\n\n001-38266\n\n \n\n \n\n \n\n \n\n \n\n \n\n3.3\n\n \n\n[Amended and Restated Bylaws of the Registrant](https://www.sec.gov/Archives/edgar/data/1701108/000095017023062897/spro-ex3_1.htm)\n\n \n\n \n\nForm 10-Q\n\n(Exhibit 3.1)\n\n11/13/2023\n\n001-38266\n\n \n\n \n\n \n\n \n\n \n\n \n\n31.1\n\n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](spro-ex31_1.htm)\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n32.1*\n\n[Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Principal Executive Officer and Principal Financial Officer](spro-ex32_1.htm)\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\nXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.SCH\n\nInline XBRL Taxonomy Extension Schema Document\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.CAL\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.DEF\n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.LAB\n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.PRE\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\nX\n\n \n\n \n\n* The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Spero Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.\n\n81\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nSPERO THERAPEUTICS, INC.\n\n \n\n \n\n \n\n \n\nDate: May 13, 2026\n\n \n\nBy:\n\n/s/ Esther Rajavelu\n\n \n\n \n\n \n\nEsther Rajavelu\n\n \n\n \n\n \n\nPresident, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer\n\n \n\n \n\n \n\n(Principal Executive, Financial and Accounting Officer)\n\n \n\n82"}